Patient-led follow-up after early breast cancer treatment
Part of Cancer, Skin clinical trials.
This study looks at a patient-led follow-up approach after early breast cancer treatment, where you may have more control and flexibility instead of routine hospital visits, while still on hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You were diagnosed with stage I, II, or III breast cancer that is hormone receptor-positive and HER2-negative.
- You finished your main breast cancer treatment (surgery, chemo, or radiation) within the last 12 months.
- You are currently taking or planning to take hormone-blocking pills (endocrine therapy).
- You can understand English and have internet access.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether some patients who finished curative breast cancer treatment can safely have fewer follow-up appointments and scans. Researchers want to see if less frequent monitoring is safe for patients without any signs of cancer returning.
This study tests whether patients who have finished breast cancer treatment and are doing well can safely have fewer doctor visits and scans. Researchers want to see if reducing routine surveillance affects quality of life and health outcomes.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
This trial tests whether a personalized follow-up plan after breast cancer surgery (instead of a fixed schedule) can improve care and support after treatment. It may help people know what follow-up is best for them as they move into survivorship.
This follow-up study is for people who took part in earlier breast cancer gene tests (TAILORx or RxPONDER). It collects health information and tumor tissue over time to learn more about how breast cancer behaves after treatment.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.